Kaya Q3FY26 Revenue Up 3% to ₹60 Crore; Posts Loss of ₹36.2 Crore
Kaya Limited's Q3 FY26 standalone and consolidated revenue grew 3% to ₹60 crore. The clinic business saw 7% revenue growth, with services up 5% and products up 34%. However, the company reported a consolidated loss of ₹36.2 crore, compared to a profit of ₹3.5 crore in Q3 FY25.
While revenue saw a modest increase, the substantial rise in losses negatively impacts investor sentiment and indicates financial challenges, warranting a medium impact.
The company reported a significant increase in losses for both standalone and consolidated results in Q3 FY26 compared to the previous year, despite a marginal revenue increase.
Kaya Limited announced its financial results for the quarter and nine months ended December 31, 2025. The company's India business clinic segment registered a revenue growth of 7% over Q3 FY25. Services business saw a 5% growth, driven by categories like Acne & Scars, Hair Care, and Brightening & Pigmentation. Notably, Acne & Scars services grew by 52% and Haircare services by 18% over Q3 FY25, aided by new service technologies and enhanced customer journeys.
The product business experienced a 34% growth over Q3 FY25, primarily fueled by categories such as Nutraceutical, Anti-Ageing, and Sun Care.
On a standalone basis, revenue from operations for Q3 FY26 was ₹60.0 crore, marking a 3% increase compared to the corresponding quarter in FY25. However, the standalone Profit After Tax (PAT) for Q3 FY26 was a loss of ₹36.2 crore, a decline from a loss of ₹15.5 crore in Q3 FY25.
Consolidated revenue from operations also stood at ₹60.0 crore for Q3 FY26, a 3% rise over the same period last year. The consolidated Profit After Tax (PAT) for Q3 FY26 was a loss of ₹36.2 crore, a significant shift from a profit of ₹3.5 crore in Q3 FY25.
What to do with a filing like this
Kaya Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Kaya Limited. Read the original for the full detail.